Skip to main content
SpringerLink
Log in

8-Aminoquinolines: Primaquine and Tafenoquine

  • Chapter
  • First Online:
Book cover Treatment and Prevention of Malaria

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

8-Aminoquinolines are an important class of antimalarial drugs because they are effective against the liver stages of Plasmodium infections and thus are administered for radical cure and presumptive antirelapse therapy against relapsing malaria. In this chapter, we discuss two 8-aminoquinolines, primaquine and tafenoquine. Primaquine was identified in 1946 and has been used extensively to clear liver-stage parasites, especially those from Plasmodium vivax. These can persist in the liver for months, as a dormant form of the parasite (the hypnozoite), which re-emerges much later to cause clinical disease. Tafenoquine, a primaquine analog, is currently under advanced clinical development. Tafenoquine has a much longer elimination half-life compared with primaquine (14 days versus 6 h) and is highly effective both in treating relapses of P. vivax malaria and as a causal prophylactic agent against P. falciparum and P. vivax malaria. A major drawback to the 8-aminoquinolines is their toxicity in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. We discuss clinical uses, pharmacokinetics and metabolism, safety and tolerability, mechanisms of action and drug resistance for both these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Peters W (1999) The evolution of tafenoquine–antimalarial for a new millennium? J R Soc Med 92:345–352

    PubMed  CAS  Google Scholar 

  2. Alving AS, Pullman TN et al (1948) The clinical trial of 18 analogues of pamaquin (plasmochin) in vivax malaria, Chesson strain. J Clin Invest 27:34–45

    Article  CAS  Google Scholar 

  3. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flannagan OL, Jeffery GM (1955) The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain). J Lab Clin Med 46:391–397

    PubMed  CAS  Google Scholar 

  4. Baird JK, Wiady I, Sutanihardja A, Suradi P, Basri H, Sekartuti AE, Fryauff DJ, Hoffman SL (2002) Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 66:659–660

    PubMed  CAS  Google Scholar 

  5. Basco LK, Bickii J, Ringwald P (1999) In-vitro activity of primaquine against the asexual blood stages of Plasmodium falciparum. Ann Trop Med Parasitol 93:179–182

    Article  PubMed  CAS  Google Scholar 

  6. Edgecomb J, Arnold J, Yount E Jr, Alving A, Eichelberger L (1950) Primaquine, SN-13272, a new curative agent in vivax malaria: a preliminary report. Nat Malar Soc 9:285–357

    Google Scholar 

  7. Wilairatana P, Silachamroon U, Krudsood S, Singhasivanon P, Treeprasertsuk S, Bussaratid V, Phumratanaprapin W, Srivilirit S, Looareesuwan S (1999) Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 61:973–977

    PubMed  CAS  Google Scholar 

  8. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ (1994) Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169:932–935

    Article  PubMed  CAS  Google Scholar 

  9. Powell RD, Brewer GJ (1967) Effects of pyrimethamine, chlorguanide, and primaquine against exoerythrocytic forms of a strain of chloroquine-resistant Plasmodium falciparum from Thailand. Am J Trop Med Hyg 16:693–698

    PubMed  CAS  Google Scholar 

  10. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Jeffery GM (1954) The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. J Lab Clin Med 44:429–438

    PubMed  CAS  Google Scholar 

  11. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ (2006) Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75:402–415

    PubMed  CAS  Google Scholar 

  12. Baird JK, Hoffman SL (2004) Primaquine therapy for malaria. Clin Infect Dis 39:1336–1345

    Article  PubMed  CAS  Google Scholar 

  13. Fryauff D, Baird J, Basri H, Sumawinata I, Purnomo RT, Ohrt C, Mouzin E, Church C, Richards A et al (1995) Randomised placebo-controlled trial of primaquine for prophalaxis of falciparum and vivax malaria. Lancet 346:1190–1193

    Article  PubMed  CAS  Google Scholar 

  14. Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, Gramzinski R, Sismadi P, Krisin LJ et al (2001) Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 33:1990–1997

    Article  PubMed  CAS  Google Scholar 

  15. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, Purnomo LB, Masbar S, Richie TL et al (1995) Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 52:479–484

    PubMed  CAS  Google Scholar 

  16. Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, Berman J (1998) Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129:241–244

    PubMed  CAS  Google Scholar 

  17. Alving AS, Arnold J, Robinson DH (1952) Mass therapy of subclinical vivax malaria with primaquine. JAMA 149:1558

    Article  CAS  Google Scholar 

  18. Jelinek T, Nothdurft HD, Von Sonnenburg F, Loscher T (1995) Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am J Trop Med Hyg 52:322–324

    PubMed  CAS  Google Scholar 

  19. Baird JK, Rieckmann KH (2003) Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19:115–120

    Article  PubMed  CAS  Google Scholar 

  20. Schwartz E, Regev-Yochay G, Kurnik D (2000) Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 62:393–395

    PubMed  CAS  Google Scholar 

  21. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ (2001) Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 65:471–476

    PubMed  CAS  Google Scholar 

  22. Clyde DF, McCarthy VC (1977) Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg 26:562–563

    PubMed  CAS  Google Scholar 

  23. Goller JL, Jolley D, Ringwald P, Biggs BA (2007) Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 76:203–207

    PubMed  CAS  Google Scholar 

  24. Dao NV, Cuong BT, Ngoa ND, le Thuy TT, The ND, Duy DN, Dai B, Thanh NX, Chavchich M, Rieckmann KH et al (2007) Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine. Trans R Soc Trop Med Hyg 101:534–539

    Article  PubMed  CAS  Google Scholar 

  25. Pukrittayakamee S, Imwong M, Chotivanich K, Singhasivanon P, Day NP, White NJ (2010) A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 82:542–547

    Article  PubMed  CAS  Google Scholar 

  26. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S (2008) High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 78:736–740

    PubMed  CAS  Google Scholar 

  27. Alving AS et al (1955) Potentialtion of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 46:301–306

    PubMed  CAS  Google Scholar 

  28. Bray PG, Deed S, Fox E, Kalkanidis M, Mungthin M, Deady LW, Tilley L (2005) Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. Biochem Pharmacol 70:1158–1166

    Article  PubMed  CAS  Google Scholar 

  29. Galappaththy GN, Omari AA, Tharyan P (2007) Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev CD004389

    Google Scholar 

  30. Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalearmrult K, Mint HY, Maneekan P, White NJ, Gourdeuk VR, Brittenham GM et al (2003) Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 69:14–18

    PubMed  CAS  Google Scholar 

  31. Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD (1968) Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ 38:625–632

    PubMed  CAS  Google Scholar 

  32. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ (2004) Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 48:1329–1334

    Article  PubMed  CAS  Google Scholar 

  33. Lederman ER, Maguire JD, Sumawinata IW, Chand K, Elyazar I, Estiana L, Sismadi P, Bangs MJ, Baird JK (2006) Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malar J 5:108

    Article  PubMed  CAS  Google Scholar 

  34. Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A, Alifrangis M, Mosha F, Sauerwein R, Bousema T (2007) Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2:e1023

    Article  PubMed  Google Scholar 

  35. El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A (2007) A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One 2:e1311

    Article  PubMed  Google Scholar 

  36. Suputtamongkol Y, Chindarat S, Silpasakorn S, Chaikachonpatd S, Lim K, Chanthapakajee K, Kaewkaukul N, Thamlikitkul V (2003) The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. Am J Trop Med Hyg 68:620–623

    PubMed  CAS  Google Scholar 

  37. Kumar N, Zheng H (1990) Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol Res 76:214–218

    Article  PubMed  CAS  Google Scholar 

  38. Dunyo S, Milligan P, Edwards T, Sutherland C, Targett G, Pinder M (2006) Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin Trials 1:e20

    Article  PubMed  CAS  Google Scholar 

  39. White NJ (2008) The role of anti-malarial drugs in eliminating malaria. Malar J 7(Suppl 1):S8

    Google Scholar 

  40. Lanners HN (1991) Effect of the 8-aminoquinoline primaquine on culture-derived gametocytes of the malaria parasite Plasmodium falciparum. Parasitol Res 77:478–481

    Article  PubMed  CAS  Google Scholar 

  41. Beaudoin RL, Aikawa M (1968) Primaquine-induced changes in morphology of exoerythrocytic stages of malaria. Science 160:1233–1234

    Article  PubMed  CAS  Google Scholar 

  42. Boulard Y, Landau I, Miltgen F, Ellis DS, Peters W (1983) The chemotherapy of rodent malaria. XXXIV. Causal prophylaxis Part III: Ultrastructural changes induced in exo-erythrocytic schizonts of Plasmodium yoelii yoelii by primaquine. Ann Trop Med Parasitol 77:555–568

    PubMed  CAS  Google Scholar 

  43. Howells RE, Pters W, Fullard J (1970) The chemotherapy of rodent malaria. 13. Fine structural changes observed in the eryhrocytic stages of Plasmodium berghei berghei following exposureto primaquine and menoctone. Ann Trop Med Parasitol 64:203–207

    PubMed  CAS  Google Scholar 

  44. Aikawa M, Beaudoin RL (1970) Plasmodium fallax: high-resolution autoradiography of exoerythrocytic stages treated with Primaquine in vitro. Exp Parasitol 27:454–463

    Article  PubMed  CAS  Google Scholar 

  45. Peters W, Ellis D, Boulard Y, Landau I (1984) The chemotherapy of rodent malaria XXXVI. Part IV. The activity of a new 8-aminoquinoline, WR 225,448 against exo-erythrocytic schizonts of Plasmodium yoelii yoelii. Ann Trop Med Parasitol 78:467–478

    PubMed  CAS  Google Scholar 

  46. Rotman A (1975) Genetics of a primaquin-resistant yeast. J Gen Microbiol 89:1–10

    PubMed  CAS  Google Scholar 

  47. Krungkrai J, Burat D, Kudan S, Krungkrai S, Prapunwattana P (1999) Mitochondrial oxygen consumption in asexual and sexual blood stages of the human malarial parasite, Plasmodium falciparum. Southeast Asian J Trop Med Public Health 30:636–642

    PubMed  CAS  Google Scholar 

  48. Idowu OR, Peggins JO, Brewer TG (1995) Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents. Drug Metab Dispos 23:18–27

    PubMed  CAS  Google Scholar 

  49. Vale N, Moreira R, Gomes P (2009) Primaquine revisited six decades after its discovery. Eur J Med Chem 44:937–953

    Article  PubMed  CAS  Google Scholar 

  50. Grewal RS (1981) Pharmacology of 8-aminoquinolines. Bull World Health Organ 59:397–406

    PubMed  CAS  Google Scholar 

  51. Fry M, Pudney M (1992) Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566 C80). Biochem Pharmacol 43:1545–1553

    Article  PubMed  CAS  Google Scholar 

  52. Fry M, Beesley JE (1991) Mitochondria of mammalian Plasmodium spp. Parasitology 102:17–26

    Article  PubMed  Google Scholar 

  53. Srivastava IK, Rottenberg H, Vaidya AB (1997) Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 272:3961–3966

    Article  PubMed  CAS  Google Scholar 

  54. Painter HJ, Morrisey JM, Mather MW, Vaidya AB (2007) Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446:88–91

    Article  PubMed  CAS  Google Scholar 

  55. Vaidya AB, Lashgari MS, Pologe LG, Morrisey J (1993) Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. Mol Biochem Parasitol 58:33–42

    Article  PubMed  CAS  Google Scholar 

  56. Fletcher KA, Barton PF, Kelly JA (1988) Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine. Biochem Pharmacol 37:2683–2690

    Article  PubMed  CAS  Google Scholar 

  57. Greenberg J, Taylor DJ, Josephson ES (1951) Studies on Plasmodium gallinaceum in vitro II. The effects of some 8-aminoquinolines against the erythrocytic parasites. J Infect Dis 88:163–167

    Article  PubMed  CAS  Google Scholar 

  58. Meshnick SR (1998) Artemisinin antimalarials: mechanisms of action and resistance. Med Trop 58:13–17

    CAS  Google Scholar 

  59. McChesney JD (1981) Considerations about the structure-activity relationships of 8- aminoquinoline antimalarial drugs. Bull World Health Organ 59:459–462

    PubMed  CAS  Google Scholar 

  60. Peters W, Irare SG, Ellis DS, Warhurst DC, Robinson BL (1984) The chemotherapy of rodent malaria, XXXVIII. Studies on the activity of three new antimalarials (WR 194,965, WR 228,258 and WR 225,448) against rodent and human malaria parasites (Plasmodium berghei and P. falciparum). Ann Trop Med Parasitol 78:567–579

    PubMed  CAS  Google Scholar 

  61. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM (1985) Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol 19:745–750

    Article  PubMed  CAS  Google Scholar 

  62. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme ML, Breckenridge AM (1985) Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol 19:751–755

    Article  PubMed  CAS  Google Scholar 

  63. Bangchang KN, Songsaeng W, Thanavibul A, Choroenlarp P, Karbwang J (1994) Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. Trans R Soc Trop Med Hyg 88:220–222

    Article  PubMed  CAS  Google Scholar 

  64. Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD (2009) Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am J Trop Med Hyg 81:747–753

    Article  PubMed  CAS  Google Scholar 

  65. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM (1984) Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol 17:441–446

    Article  PubMed  CAS  Google Scholar 

  66. Greaves J, Evans DA, Gilles HM, Fletcher KA, Bunnag D, Harinasuta T (1980) Plasma kinetics and urinary excretion of primaquine in man. Br J Clin Pharmacol 10:399–404

    Article  PubMed  CAS  Google Scholar 

  67. Mayorga P, Deharo E, Landau I, Couarraze G (1997) Preliminary evaluation of primaquine activity on rodent malaria model after transdermal administration. Parasite 4:87–90

    PubMed  CAS  Google Scholar 

  68. Nishi KK, Jayakrishnan A (2007) Self-gelling primaquine-gum arabic conjugate: an injectable controlled delivery system for primaquine. Biomacromolecules 8:84–90

    Article  PubMed  CAS  Google Scholar 

  69. Singh KK, Vingkar SK (2008) Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm 347:136–143

    Article  PubMed  CAS  Google Scholar 

  70. Stensrud G, Sande SA, Kristensen S, Smistad G (2000) Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int J Pharm 198:213–228

    Article  PubMed  CAS  Google Scholar 

  71. Vangapandu S, Sachdeva S, Jain M, Singh S, Singh PP, Kaul CL, Jain R (2004) 8-Quinolinamines conjugated with amino acids are exhibiting potent blood-schizontocidal antimalarial activities. Bioorg Med Chem 12:239–247

    Article  PubMed  CAS  Google Scholar 

  72. Rajic Z, Kos G, Zorc B, Singh PP, Singh S (2009) Macromolecular prodrugs. XII. Primaquine conjugates: synthesis and preliminary antimalarial evaluation. Acta Pharm 59:107–115

    Article  PubMed  CAS  Google Scholar 

  73. Borissova R, Lammek B, Stjarnkvist P, Sjoholm I (1995) Biodegradable microspheres. 16. Synthesis of primaquine-peptide spacers for lysosomal release from starch microparticles. J Pharm Sci 84:249–255

    Article  PubMed  CAS  Google Scholar 

  74. Brueckner RP, Ohrt C, Baird JK, Milhous WK (2001) 8-aminoquinolines. In: RP J (eds) Antimalarial chemotherapy: mechanisms of action, resistance and new directions. Humana, Totowa, NJ, pp 123–151

    Google Scholar 

  75. Cappellini MD, Fiorelli G (2008) Glucose-6-phosphate dehydrogenase deficiency. Lancet 371:64–74

    Article  PubMed  CAS  Google Scholar 

  76. Beutler E, Duparc S (2007) Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 77:779–789

    PubMed  CAS  Google Scholar 

  77. Beutler E, Dern RJ, Alving AS (1955) The hemolytic effect of primaquine. VI. An in vitro test for sensitivity of erythrocytes to primaquine. J Lab Clin Med 45:40–50

    PubMed  CAS  Google Scholar 

  78. Beutler E, Dern RJ, Flanagan CL, Alving AS (1955) The hemolytic effect of primaquine. VII. Biochemical studies of drug-sensitive erythrocytes. J Lab Clin Med 45:286–295

    PubMed  CAS  Google Scholar 

  79. Srivastava P, Singh S, Jain GK, Puri SK, Pandey VC (2000) A simple and rapid evaluation of methemoglobin toxicity of 8-aminoquinolines and related compounds. Ecotoxicol Environ Saf 45:236–239

    Article  PubMed  CAS  Google Scholar 

  80. Clayman C, Arnold J, Hockwald R, Yount E Jr, Edgecomb J, Alving A (1952) Toxicity of primaquine in Caucasians. JAMA 149:1563–1568

    Article  CAS  Google Scholar 

  81. Clyde DF (1981) Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 59:391–395

    PubMed  CAS  Google Scholar 

  82. Taylor WR, White NJ (2004) Antimalarial drug toxicity: a review. Drug Saf 27:25–61

    Article  PubMed  CAS  Google Scholar 

  83. Prakash S, Chakrabarti AK, Choudhury DS (1961) Studies on Plasmodium berghei Vincke and Lips, 1948. XXXI. Selection of a primaquine resistant strain. Indian J Malariol 15:115–122

    PubMed  CAS  Google Scholar 

  84. Peters W (1966) Drug responses of mepacrine- and primaquine-resistant strains of Plasmodium berghei Vincke and Lips, 1948. Ann Trop Med Parasitol 60:25–30

    PubMed  CAS  Google Scholar 

  85. Arnold J, Alvinig AS, Clayman CB (1961) Induced primaquine resistance in vivax malaria. Trans R Soc Trop Med Hyg 55:345–350

    Article  PubMed  CAS  Google Scholar 

  86. Baird JK (2007) A rare glimpse at the efficacy of primaquine. Am J Trop Med Hyg 76:201–202

    PubMed  Google Scholar 

  87. Kitchener S (2002) Malaria in the Australian Defence Force associated with the InterFET peacekeeping operation in East Timor. Mil Med 167:iii–iv

    Google Scholar 

  88. Spudick JM, Garcia LS, Graham DM, Haake DA (2005) Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. J Clin Microbiol 43:978–981

    Article  PubMed  Google Scholar 

  89. Crockett M, Kain KC (2007) Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs 16:705–715

    Article  PubMed  CAS  Google Scholar 

  90. The GlaxoSmithKline (GSK) Clinical Study Register. http://www.gsk-clinicalstudyregister.com. Accessed 23 Apr 2010

  91. Medicines for Malaria Venture Project Portfolio. http://www.mmv.org/research-development/project-portfolio/tafenoquine. Accessed 23 Apr 2010

  92. Vennerstrom JL, Nuzum EO, Miller RE, Dorn A, Gerena L, Dande PA, Ellis WY, Ridley RG, Milhous WK (1999) 8-aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization [In Process Citation]. Antimicrob Agents Chemother 43:598–602

    PubMed  CAS  Google Scholar 

  93. Vennerstrom JL, Eaton JW (1988) Oxidants, oxidant drugs, and malaria. J Med Chem 31:1269–1277

    Article  PubMed  CAS  Google Scholar 

  94. Pradines B, Mamfoumbi MM, Tall A, Sokhna C, Koeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF et al (2006) In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother 50:3225–3226

    Article  PubMed  CAS  Google Scholar 

  95. Peters W, Robinson BL, Milhous WK (1993) The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol 87:547–552

    PubMed  CAS  Google Scholar 

  96. Coleman RE, Clavin AM, Milhous WK (1992) Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes. Am J Trop Med Hyg 46:169–182

    PubMed  CAS  Google Scholar 

  97. Heisy GE, Milhous WK, Hansuklarita P, Theoharides AD, Schuster BG, Davidson DE (1988) Radical curative properties of Tafenoquine (WR 238605, SB252263), Abstr. No. 323. The American Society of Tropical Medicine and Hygiene, Washington DC, p 217

    Google Scholar 

  98. Brueckner RP, Lasseter KC, Lin ET, Schuster BG (1998) First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 58:645–649

    PubMed  CAS  Google Scholar 

  99. Coatney GE, Collins WE, Warren M, Contacos PG (1971) Primate malarias. Department of Health and Welfare, US Govt Publication, Washington, DC

    Google Scholar 

  100. Puri SK, Dutta GP (2003) Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys. Acta Trop 86:35–40

    Article  PubMed  CAS  Google Scholar 

  101. Obaldia N 3rd, Rossan RN, Cooper RD, Kyle DE, Nuzum EO, Rieckmann KH, Shanks GD (1997) WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 56:508–510

    PubMed  CAS  Google Scholar 

  102. Lee CC, Kinter LD, Heiffer MH (1981) Subacute toxicity of primaquine in dogs, monkeys, and rats. Bull World Health Organ 59:439–448

    PubMed  CAS  Google Scholar 

  103. Augusto O, Weingrill CL, Schreier S, Amemiya H (1986) Hydroxyl radical formation as a result of the interaction between primaquine and reduced pyridine nucleotides. Catalysis by hemoglobin and microsomes. Arch Biochem Biophys 244:147–155

    Article  PubMed  CAS  Google Scholar 

  104. Baird JK, Davidson DJ, Decker JJ (1986) Oxidative activity of hydroxylated primaquine analogs. Non-toxicity to glucose-6-phosphate dehydrogenase-deficient human red blood cells in vitro. Biochem Pharmacol 35:1091–1098

    Article  PubMed  CAS  Google Scholar 

  105. Hiebsch RR, Raub TJ, Wattenberg BW (1991) Primaquine blocks transport by inhibiting the formation of functional transport vesicles. Studies in a cell-free assay of protein transport through the Golgi apparatus. J Biol Chem 266:20323–20328

    PubMed  CAS  Google Scholar 

  106. van Weert AW, Geuze HJ, Groothuis B, Stoorvogel W (2000) Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomes. Eur J Cell Biol 79:394–399

    PubMed  Google Scholar 

  107. Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG (2001) Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br J Clin Pharmacol 52:663–670

    Article  PubMed  CAS  Google Scholar 

  108. Charles BG, Miller AK, Nasveld PE, Reid MG, Harris IE, Edstein MD (2007) Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother 51:2709–2715

    Article  PubMed  CAS  Google Scholar 

  109. Idowu OR, Peggins JO, Brewer TG, Kelley C (1995) Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes. Drug Metab Dispos 23:1–17

    PubMed  CAS  Google Scholar 

  110. Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG (2000) Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 355:2041–2045

    Article  PubMed  CAS  Google Scholar 

  111. Shanks GD, Kain KC, Keystone JS (2001) Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis 33:381–385

    Article  PubMed  CAS  Google Scholar 

  112. Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R (2001) A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 33:1968–1974

    Article  PubMed  CAS  Google Scholar 

  113. Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG (1998) Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother 42:1293–1294

    PubMed  CAS  Google Scholar 

  114. Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL et al (2003) A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 36:541–549

    Article  PubMed  CAS  Google Scholar 

  115. Walsh SD, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumgsichol P, Chuenchitra SC, Edstein MD, et al (2004) Randomized, double-blind, placebo controlled evaluation of monthly tafenoquine (WR 238605) for Plasmodium falciparum and P. vivax malaria in Royal Thai Army soldiers. J Inf Dis 190:1456-1463

    Google Scholar 

  116. Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C et al (2010) Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother 54:792–798

    Article  PubMed  CAS  Google Scholar 

  117. Leary KJ, Riel MA, Roy MJ, Cantilena LR, Bi D, Brater DC, van de Pol C, Pruett K, Kerr C, Veazey JM Jr et al (2009) A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers. Am J Trop Med Hyg 81:356–362

    PubMed  CAS  Google Scholar 

  118. Nasveld P, Kitchener S, Edstein M, Rieckmann K (2002) Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans R Soc Trop Med Hyg 96:683–684

    Article  PubMed  Google Scholar 

  119. Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD (2008) Comparison of three different dose regimens of tafenoquine versus primaquine for post exposure prophylaxis of vivax malaria in the South West Pacific. Trans Roy Soc Trop Med Hyg 102:1095–1101

    Google Scholar 

  120. Edstein MD, Nasveld PE, Kocisko DA, Kitchener SJ, Gatton ML, Rieckmann KH (2007) Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis. Trans R Soc Trop Med Hyg 101:226–230

    Article  PubMed  CAS  Google Scholar 

  121. Walsh DS, Looareesuwan S, Wilairatana P, Heppner DG Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, Milhous WK et al (1999) Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 180:1282–1287

    Article  PubMed  CAS  Google Scholar 

  122. Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S (2004) Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 39:1095–1103

    Article  PubMed  CAS  Google Scholar 

  123. Nasveld P, Kitchener S (2005) Treatment of acute vivax malaria with tafenoquine. Trans R Soc Trop Med Hyg 99:2–5

    Article  PubMed  Google Scholar 

  124. Kitchener S, Nasveld P, Edstein MD (2007) Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg 76:494–496

    PubMed  CAS  Google Scholar 

  125. Nosten F, White NJ (2007) Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77:181–192

    PubMed  CAS  Google Scholar 

  126. Roberts L, Enserink M (2007) Malaria. Did they really say … eradication? Science 318:1544–1545

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Professor Dennis Shanks for review and helpful discussions with the manuscript. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official, or as reflecting true views of the United States Department of the Army, the Department of Defense or the Australian Defense Force.

Author information

Authors and Affiliations

  1. Australian Army Malaria Institute, Gallipoli Barracks, Weary Dunlop Drive, Enoggera, QLD, 4051, Australia

    Norman C. Waters & Michael D. Edstein

Authors
  1. Norman C. Waters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael D. Edstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norman C. Waters .

Editor information

Editors and Affiliations

  1. Centre for Infection, Div. Cellular & Molecular Medicine, St. George's University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom

    Henry M. Staines

  2. Medical School, Dept. Infectious Diseases, St. George´s Hospital, Cranmer Terrace, London, SW17 0RE, United Kingdom

    Sanjeev Krishna

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Basel AG

About this chapter

Cite this chapter

Waters, N.C., Edstein, M.D. (2011). 8-Aminoquinolines: Primaquine and Tafenoquine. In: Staines, H., Krishna, S. (eds) Treatment and Prevention of Malaria. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0346-0480-2_4

Download citation

Publish with us

Policies and ethics

Search

Navigation